Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 14.43B | 19.91B | 26.46B | 23.74B | 14.74B | 12.25B |
Gross Profit | 5.52B | 4.09B | -1.70B | 9.75B | 1.41B | 3.52B |
EBITDA | 2.01B | 2.42B | 7.08B | 410.00M | 721.00M | 488.00M |
Net Income | -118.50M | 1.33B | 3.93B | -782.00M | 586.00M | 41.00M |
Balance Sheet | ||||||
Total Assets | 16.21B | 18.73B | 21.37B | 29.04B | 27.09B | 17.12B |
Cash, Cash Equivalents and Short-Term Investments | 5.38B | 6.22B | 6.85B | 4.84B | 5.06B | 1.82B |
Total Debt | 2.93B | 3.51B | 4.10B | 3.96B | 4.58B | 5.29B |
Total Liabilities | 12.52B | 13.92B | 17.13B | 27.76B | 24.34B | 15.74B |
Stockholders Equity | 3.30B | 4.42B | 3.88B | 1.02B | 2.37B | 957.00M |
Cash Flow | ||||||
Free Cash Flow | 276.00M | 733.00M | 2.42B | 943.00M | 1.19B | 778.00M |
Operating Cash Flow | 633.00M | 1.15B | 2.75B | 1.31B | 1.61B | 1.27B |
Investing Cash Flow | -166.00M | 493.00M | 115.00M | -566.00M | 2.26B | -354.00M |
Financing Cash Flow | -989.00M | -1.55B | -1.41B | -917.00M | -938.00M | -280.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | 51.55B | 16.85 | 7.68% | 4.53% | -7.42% | 5.84% | |
69 Neutral | 18.33B | 15.41 | 9.86% | 3.85% | -3.11% | -31.10% | |
61 Neutral | 7.84B | 29.61 | 13.24% | 4.56% | 10.04% | 0.00% | |
60 Neutral | 7.70B | 33.40 | 12.95% | 4.80% | 3.78% | 50.18% | |
58 Neutral | 2.20B | -32.58 | -4.00% | 7.39% | 15.42% | -406.43% | |
52 Neutral | £7.91B | 6.18 | -5.95% | 2.89% | -4.82% | -123.58% | |
66 Neutral | $17.65B | 18.10 | 5.60% | 3.62% | 6.62% | 11.55% |
Centrica plc has announced the purchase of 5,207,728 of its own ordinary shares at a price of 156.4000 pence per share, which will be held as treasury shares. This transaction is part of the first tranche of the company’s 2025 buyback programme, executed through Goldman Sachs International. Since June 2025, Centrica has acquired a total of 141,825,273 shares at a cost of over £227 million, reflecting its strategy to enhance shareholder value and manage its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 5,207,728 of its own ordinary shares at a price of 156.4000 pence per share, as part of its ongoing 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is part of the first tranche of the programme’s extension announced earlier this year. The acquisition of these shares, which will be held as treasury shares, reflects Centrica’s strategic focus on optimizing its capital structure and returning value to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that its Share Incentive Plan administrators, Equiniti Limited, have acquired ordinary shares on behalf of its executive directors, Christopher O’Shea and Russell O’Brien. The transactions involve the acquisition of Partnership Shares and Matching Shares, with a total of 117 shares for O’Shea and 118 shares for O’Brien, conducted on the London Stock Exchange and outside a trading venue. This move highlights the company’s commitment to aligning the interests of its executives with those of its shareholders, potentially impacting stakeholder confidence and executive engagement.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 4,089,458 of its own ordinary shares at a price of 155.9600 pence per share, which will be held as treasury shares. This transaction is part of the first tranche of the company’s 2025 buyback programme, which was extended earlier in the year. Since June 2025, Centrica has acquired a total of 136,617,545 shares at a cost of £219,591,838.72. The buyback programme is a strategic move to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,719,058 of its own ordinary shares at a price of 154.4200 pence per share, as part of the first tranche of its 2025 buyback programme. This move, executed through Goldman Sachs International, is part of Centrica’s ongoing strategy to manage its capital structure and return value to shareholders, further solidifying its position in the energy market.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,426,168 of its own ordinary shares at a price of 154.7700 pence each, as part of the first tranche of its extended 2025 buyback program. This move, executed through Goldman Sachs International, is part of Centrica’s strategy to manage its capital structure and return value to shareholders, reflecting confidence in its financial health and future prospects.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,762,183 ordinary shares at a price of 154.9100 pence per share, as part of the first tranche of its 2025 buyback programme. This move, executed through Goldman Sachs International, is part of a broader strategy to manage its capital structure and return value to shareholders. Following this transaction, Centrica holds 477,079,856 shares in treasury, with a total of 4,780,527,358 shares in issue. The buyback programme reflects Centrica’s commitment to enhancing shareholder value and optimizing its financial resources.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,229,051 of its ordinary shares at an average price of 155.4000 pence per share, as part of its ongoing 2025 buyback program. This transaction, executed through Goldman Sachs International, is part of a broader strategy to manage its capital structure and enhance shareholder value. Following this purchase, Centrica holds 474,343,314 shares in treasury, with 4,783,263,900 shares remaining in issue. This move may impact the company’s financial metrics and shareholder returns, signaling confidence in its financial health and future prospects.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,340,508 of its own ordinary shares at a price of 155.2600 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of an ongoing effort to manage its share capital and enhance shareholder value by holding the purchased shares as treasury shares.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.